American Century Companies Inc. increased its position in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 9.5% during ...
Xponance Inc. lifted its position in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 25.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 6,148 shares of ...
Hosted on MSN1mon
Biohaven Just Hurdled An FDA Setback — And Its Moving LinesBiohaven stock hurdled its 50-day and 200-day lines Tuesday after the Food and Drug Administration granted its spinocerebellar ataxia treatment a speedier review time. Spinocerebellar ataxia ...
Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of total IgG, differentiating Biohaven's new small-molecule class of degraders from the monoclonal ...
NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...
Highlights,Institutional investments in Biohaven Ltd. have shown recent increases.,The company focuses on developing therapies in neuroscience, immunology, and oncology.,Research pipeline includes ...
Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal antibody ...
Before market open, Biohaven announced that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for troriluzole. This is a once-daily oral treatment for adults ...
Biohaven’s bipolar disorder candidate has failed to improve mania symptoms in a phase 2/3 trial. The registrational study assessed BHV-7000, a drug designed to selectively activate Kv7.2/Kv7.3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback